Measles, Drug Shortages, AI at FDA, and New Rare Disease Treatments | FDA In Your Day - Ep. 1

U.S. Food and Drug Administration
U.S. Food and Drug Administration
1,556
0
Published 2024-03-28
Check out my new video series…FDA In Your Day! I’ll regularly post videos with important updates from the agency. The first video covers measles vaccines, drug shortages, AI, and FDA-approved products for two rare diseases.

0:00 Intro
0:08 Measles Vaccines
0:35 Drug Shortages
1:01 AI at the FDA
1:23 New Treatments

Transcript:
Here are four important updates from the FDA.
I’m Dr. Namandjé Bumpus, Principal Deputy Commissioner, and this is FDA in Your Day.
We continue to see measles outbreaks in the United States. The measles virus is extremely contagious and can be life-threatening, but we can do something about this! The FDA-approved measles vaccines are both safe and effective. And in fact, in most cases, people who get the measles vaccine will have lifelong protection and will never get sick, even after exposure to the virus. You can help by encouraging your loved ones to consider vaccination.
From managing measles to a new proactive solution... The FDA has made it easier for you and your healthcare provider to report potential drug shortages. Our NextGen online system allows anyone experiencing a drug shortage to make this concern known. Early notification of drug shortages or potential supply challenges can help FDA staff quickly resolve or reduce the duration of the shortage.
Let’s talk about technology you may be more familiar with: AI or artificial intelligence. For years, The FDA has been working to harness the potential of artificial intelligence, while also anticipating the challenges it brings. A new paper details our commitment to promoting the responsible and ethical development and use of AI across medical products.
And lastly, something I’m happy to share - that two new products have been approved for people with certain rare diseases. The first treatment provides an option for children who have a rare genetic disease called metachromatic leukodystrophy, or MLD. The second is the first nonsteroidal drug approved to treat patients with all genetic variants of Duchenne Muscular Dystrophy. These treatments are the first of their kind.
Thank you for watching our first episode of FDA in Your Day. Every other week, we’ll come to you with important and interesting things happening at the FDA, to protect and promote public health. You can learn more about these stories at FDA.gov. Thanks.